Pupillary changes as a potential biomarker for escitalopram in relation to CYP2C19 polymorphism
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Escitalopram (Primary)
- Indications Anxiety disorders; Depression; Depressive disorders
- Focus Pharmacodynamics; Pharmacokinetics
- 01 Sep 2009 Results have been published in the European Journal of Clinical Pharmacology.
- 12 Jul 2009 Results presented at 9th Congress of the European Association for Clinical Pharmacology and Therapeutics.
- 05 Feb 2008 Status changed from initiated to completed as reported by ClinicalTrials.gov.